Detail Information of Exogenous Modulation

General Information of Drug Transporter (DT)
DT ID DTD0029 Transporter Info
Gene Name SLCO1A2
Transporter Name Organic anion transporting polypeptide 1A2
Gene ID
6579
UniProt ID
P46721
Exogenous factors (drugs, dietary constituents, etc.) Modulation of This DT (EGM)

Approved Drug

  Rifampicin

            3 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Rifampicin inhibits the transportation of Bromsulphthalein by SLCO1A2 (Ki = 51 microM) [1]

Affected Drug/Substrate

 Bromsulphthalein Modulation Type Inhibition

Cell System

 Oocytes-OATP1A2

  DT Modulation 2

 Rifampicin inhibits the transportation of Sulfobromophthalein by SLCO1A2 (Ki = 51 microM) [1]

Affected Drug/Substrate

 Sulfobromophthalein Modulation Type Inhibition

Cell System

 Oocytes-OATP1A2

  DT Modulation 3

 Rifampicin induces the activity of SLCO1A2 [4] , [5]

  Rifamycin SV

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Rifamycin SV inhibits the transportation of Bromsulphthalein by SLCO1A2 (Ki = 11 microM) [1]

Affected Drug/Substrate

 Bromsulphthalein Modulation Type Inhibition

Cell System

 Oocytes-OATP1A2

  DT Modulation 2

 Rifamycin SV inhibits the activity of SLCO1A2 [4]

  Ritonavir

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Ritonavir inhibits the transportation of Fexofenadine by SLCO1A2 (IC50 < 10 microM) [8]

Affected Drug/Substrate

 Fexofenadine Modulation Type Inhibition

Cell System

 Human cervical cancer cell line (Hela)-OATP1A2

  DT Modulation 2

 Ritonavir inhibits the activity of SLCO1A2 [12]

  Indocyanine green

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Indocyanine green inhibits the transportation of Sodium taurocholate by SLCO1A2 [9]

Affected Drug/Substrate

 Sodium taurocholate Modulation Type Inhibition

Cell System

 Oocytes-OATP1A2

  DT Modulation 2

 Indocyanine green inhibits the transportation of Sulfobromophthalein by SLCO1A2 [9]

Affected Drug/Substrate

 Sulfobromophthalein Modulation Type Inhibition

Cell System

 Oocytes-OATP1A2

  Quercetin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Quercetin inhibits the transportation of Atorvastatin by SLCO1A2 (IC50 = 13.5 microM; Ki = 32.4 microM) [6]

Affected Drug/Substrate

 Atorvastatin Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OATP1A2

  Saquinavir

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Saquinavir inhibits the transportation of Fexofenadine by SLCO1A2 (IC50 < 10 microM) [8]

Affected Drug/Substrate

 Fexofenadine Modulation Type Inhibition

Cell System

 Human cervical cancer cell line (Hela)-OATP1A2

  Hesperidin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Hesperidin inhibits the transportation of Fexofenadine by SLCO1A2 (IC50 = 2.7 microM) [2]

Affected Drug/Substrate

 Fexofenadine Modulation Type Inhibition

Cell System

 Human cervical cancer cell line (Hela)-OATP1A2

  Verapamil

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Verapamil inhibits the transportation of Fexofenadine by SLCO1A2 (IC50 = 2.6 microM) [2]

Affected Drug/Substrate

 Fexofenadine Modulation Type Inhibition

Cell System

 Human cervical cancer cell line (Hela)-OATP1A2

  Mesalazine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Mesalazine inhibits the transportation of Bromsulphthalein by SLCO1A2 [15]

Affected Drug/Substrate

 Bromsulphthalein Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OATP1A2

  Naloxone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Naloxone inhibits the transportation of Deltorphin by SLCO1A2 [16]

Affected Drug/Substrate

 Deltorphin Modulation Type Inhibition

Cell System

 Oocytes-OATP1A2

  Lovastatin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Lovastatin inhibits the transportation of Fexofenadine by SLCO1A2 [8]

Affected Drug/Substrate

 Fexofenadine Modulation Type Inhibition

Cell System

 Oocytes-OATP1A2

  Hesperetin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Hesperetin inhibits the transportation of Fexofenadine by SLCO1A2 [2]

Affected Drug/Substrate

 Fexofenadine Modulation Type Inhibition

Cell System

 Human cervical cancer cell line (Hela)-OATP1A2

  Probenecid

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Probenecid inhibits the transporation of ginkolide B by SLCO1A2 [18]

Affected Drug/Substrate

 Ginkgolide B Modulation Type Inhibition

Cell System

 Human enterocyte-like 2 cell (Caco-2)

  Carbamazepine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Carbamazepine increases the expression of SLCO1A2 [19]

Regulation Mechanism

 via enhancement of Nuclear receptor subfamily 1 group I member 2 (NR1I2) Transcription Factor Info

Cell System

 Human liver samples

  Vitamin D

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Vitamin D increases the expression of SLCO1A2 [20]

Regulation Mechanism

 via enhancement of Vitamin D3 receptor (VDR) Transcription Factor Info

Cell System

 Human colon adenocarcinoma cells (Caco-2)

  Carmustine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Carmustine inhibits the expression of SLCO1A2 [21]

  Testosterone enanthate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Testosterone enanthate affects the expression of SLCO1A2 [22]

  Omeprazole

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Omeprazole increases the expression of SLCO1A2 [23]

  Vorinostat

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Vorinostat increases the expression of SLCO1A2 [24]

  Ethinyl Estradiol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Ethinyl Estradiol inhibits the expression of SLCO1A2 [25]

  Calcitriol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Calcitriol increases the expression of SLCO1A2 [26]

  Valproic Acid

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Valproic Acid inhibits the expression of SLCO1A2 [27]

  Clarithromycin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Clarithromycin inhibits the activity of SLCO1A2 [7]

  Rifaximin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Rifaximin inhibits the activity of SLCO1A2 [28]

  Pravastatin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Pravastatin inhibits the activity of SLCO1A2 [29] , [30]

  Mifepristone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Mifepristone inhibits the activity of SLCO1A2 [31]

  Cyclosporine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cyclosporine inhibits the activity of SLCO1A2 [31] , [32]

Drug in Phase 3 Trial

  Curcumin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Curcumin increases the expression of SLCO1A2 [34]

Drug in Phase 1/2 Trial

  PRI-724

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 PRI-724 inhibits the activity of SLCO1A2 [33]

Cell System

 Human embryonic kidney 293 cells (HEK293)-

Discontinued Drug

  Valspodar

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Valspodar inhibits the transportation of Fexofenadine by SLCO1A2 [8]

Affected Drug/Substrate

 Fexofenadine Modulation Type Inhibition

Cell System

 Oocytes-OATP1A2

Investigative Drug

  Naringin

            3 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Naringin inhibits the transportation of Fexofenadine by SLCO1A2 (IC50 = 3.6 microM) [2]

Affected Drug/Substrate

 Fexofenadine Modulation Type Inhibition

Cell System

 Human cervical cancer cell line (Hela)-OATP1A2

  DT Modulation 2

 Naringin inhibits the activity of SLCO1A2 (IC50 = 343 microM) [3]

Cell System

 Oocytes-OATP1A2

  DT Modulation 3

 Naringin inhibits the transportation of Fexofenadine by SLCO1A2 [2]

Affected Drug/Substrate

 Fexofenadine Modulation Type Inhibition

Cell System

 Human cervical cancer cell line (Hela)-OATP1A2

  Bromsulphthalein

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Bromsulphthalein inhibits the transportation of Estrone sulfate by SLCO1A2 (IC50 = 3.75 microM) [7]

Affected Drug/Substrate

 Estrone sulfate Modulation Type Inhibition

Cell System

 Monkey kidney tissue Fibroblast-like cell lines (COS1)-OATP1A2

  DT Modulation 2

 Bromsulphthalein inhibits the activity of SLCO1A2 [13]

  Apigenin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Apigenin inhibits the transportation of Atorvastatin by SLCO1A2 (IC50 = 9.3 microM; Ki = 22 microM) [6]

Affected Drug/Substrate

 Atorvastatin Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OATP1A2

  Kaempferol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Kaempferol inhibits the transportation of Atorvastatin by SLCO1A2 (IC50 = 37.3 microM; Ki = 25.2 microM) [6]

Affected Drug/Substrate

 Atorvastatin Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OATP1A2

  Pregnenolone Carbonitrile

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Pregnenolone Carbonitrile increases the expression of SLCO1A2 [23]

  Phenylmercuric Acetate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Phenylmercuric Acetate inhibits the expression of SLCO1A2 [35]

  21H7

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 21H7 inhibits the activity of SLCO1A2 [33]

Cell System

 Human embryonic kidney 293 cells (HEK293)-

  FH535

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 FH535 inhibits the activity of SLCO1A2 [33]

Cell System

 Human embryonic kidney 293 cells (HEK293)-

Natural Product

  Epicatechin gallate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 (-)-epicatechin-3-gallate inhibits the activity of SLCO1A2 in a substrate-dependent manner (IC50 = 10 microM) [14]

Cell System

 Human embryonic kidney 293 cells (HEK293)-OATP1A2

  Epigallocatechin gallate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 (-)-epigallocatechin-3-gallate inhibits the activity of SLCO1A2 in a substrate-dependent manner (IC50 = 55 microM) [14]

Cell System

 Human embryonic kidney 293 cells (HEK293)-OATP1A2

  Green tea

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Green tea inhibits the uptake of estrone sulphate by SLCO1A2 (IC50 = 10.2 microM) [14]

Affected Drug/Substrate

 Estrone Sulfate Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)

  DT Modulation 2

 Green tea inhibits the transportation of Nadolol by SLCO1A2 [17]

Affected Drug/Substrate

 Nadolol Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OATP1A2

Dietary Constituent

  Apple juice

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Apple juice inhibits the uptake of Bromosulphophthalein by SLCO1A2 (Ki = 22 microM) [6]

Affected Drug/Substrate

 Bromosulphophthalein Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)

  Grapefruit juice

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Grapefruit inhibits the transportation of Fexofenadine by SLCO1A2 [10]

Affected Drug/Substrate

 Fexofenadine Modulation Type Inhibition

Cell System

 Human enterocyte-like 2 cell (Caco-2)-OATP1A2

  DT Modulation 2

 Grapefruit juice inhibits the activity of SLCO1A2 [11]

Cell System

 Human cervical cancer cell line (Hela)-OATP1A2

  Orange juice

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Orange juice inhibits the transportation of Fexofenadine by SLCO1A2 [10]

Affected Drug/Substrate

 Fexofenadine Modulation Type Inhibition

Cell System

 Human enterocyte-like 2 cell (Caco-2)-OATP1A2

  DT Modulation 2

 Orange juice inhibits the activity of SLCO1A2 [11]

Cell System

 Human cervical cancer cell line (Hela)-OATP1A2

Acute Toxic Substance

  Okadaic Acid

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Okadaic Acid inhibits the expression of SLCO1A2 [37]

  Acrylamide

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Acrylamide inhibits the expression of SLCO1A2 [38]

Health and Environmental Toxicant

  Diethylhexyl Phthalate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Diethylhexyl Phthalate inhibits the expression of SLCO1A2 [36]
References
1 Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology. 2002 Jul;36(1):164-72.
2 Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice. Clin Pharmacol Ther. 2007 Apr;81(4):495-502.
3 Species difference in the effect of grapefruit juice on intestinal absorption of talinolol between human and rat. J Pharmacol Exp Ther. 2010 Jan;332(1):181-9.
4 Rifamycin SV and rifampicin exhibit differential inhibition of the hepatic rat organic anion transporting polypeptides, Oatp1 and Oatp2. Hepatology. 2000 Jul;32(1):82-6.
5 Microcystin-LR induced cellular effects in mammalian and fish primary hepatocyte cultures and cell lines: a comparative study. Toxicology. 2006 Feb 1;218(2-3):134-48.
6 Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. Biochem Pharmacol. 2010 Dec 1;80(11):1746-53.
7 Interaction of macrolide antibiotics with intestinally expressed human and rat organic anion-transporting polypeptides. Drug Metab Dispos. 2009 Dec;37(12):2375-82.
8 OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos. 1999 Aug;27(8):866-71.
9 Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology. 1995 Oct;109(4):1274-82.
10 Fruit juice inhibition of uptake transport: a new type of food-drug interaction. Br J Clin Pharmacol. 2010 Nov;70(5):645-55.
11 Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther. 2002 Jan;71(1):11-20.
12 Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes. Can J Physiol Pharmacol. 2010 Jun;88(6):682-91.
13 Blood-brain barrier is involved in the efflux transport of a neuroactive steroid, dehydroepiandrosterone sulfate, via organic anion transporting polypeptide 2. J Neurochem. 2000 Nov;75(5):1907-16.
14 Interactions of green tea catechins with organic anion-transporting polypeptides. Drug Metab Dispos. 2011 May;39(5):920-6.
15 Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake. Drug Metab Dispos. 2011 Jun;39(6):1097-102.
16 Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier. J Pharmacol Exp Ther. 2000 Jul;294(1):73-9.
17 Green tea ingestion greatly reduces plasma concentrations of nadolol in healthy subjects. Clin Pharmacol Ther. 2014 Apr;95(4):432-8.
18 The potential drug-drug interactions of ginkgolide B mediated by renal transporters. Phytother Res. 2015 May;29(5):662-7.
19 Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine. Clin Pharmacol Ther. 2006 Nov;80(5):440-456.
20 The SLCO1A2 gene, encoding human organic anion-transporting polypeptide 1A2, is transactivated by the vitamin D receptor. Mol Pharmacol. 2012 Jul;82(1):37-46.
21 Gene expression profile induced by BCNU in human glioma cell lines with differential MGMT expression. J Neurooncol. 2005 Jul;73(3):189-98.
22 Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss. J Clin Endocrinol Metab. 2007 Jul;92(7):2793-802.
23 Use of mRNA expression to detect the induction of drug metabolising enzymes in rat and human hepatocytes. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):86-96.
24 Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
25 UDCA and CDCA alleviate 17alpha-ethinylestradiol-induced cholestasis through PKA-AMPK pathways in rats. Toxicol Appl Pharmacol. 2016 Nov 15;311:12-25.
26 Vitamin D3 transactivates the zinc and manganese transporter SLC30A10 via the Vitamin D receptor. J Steroid Biochem Mol Biol. 2016 Oct;163:77-87.
27 Stem Cell Transcriptome Responses and Corresponding Biomarkers That Indicate the Transition from Adaptive Responses to Cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
28 KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG03008)
29 Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther. 2009 Feb;328(2):652-62.
30 Intestinal absorption of HMG-CoA reductase inhibitor pravastatin mediated by organic anion transporting polypeptide. Pharm Res. 2010 Oct;27(10):2141-9.
31 Development of a cell-based high-throughput assay to screen for inhibitors of organic anion transporting polypeptides 1B1 and 1B3. Curr Chem Genomics. 2010 Mar 1;4:1-8.
32 Potential for pharmacokinetic interactions between ambrisentan and cyclosporine. Clin Pharmacol Ther. 2010 Oct;88(4):513-20.
33 Impaired Transport Activity of Human Organic Anion Transporters (OATs) and Organic Anion Transporting Polypeptides (OATPs) by Wnt Inhibitors. J Pharm Sci. 2021 Feb;110(2):914-924.
34 Curcumin restores corticosteroid function in monocytes exposed to oxidants by maintaining HDAC2. Am J Respir Cell Mol Biol. 2008 Sep;39(3):312-23.
35 A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
36 Di-(2-ethylhexyl)-phthalate induces apoptosis via the PPAR Gamma/PTEN/AKT pathway in differentiated human embryonic stem cells. Food Chem Toxicol. 2019 Sep;131:110552.
37 Comparison of long-term versus short-term effects of okadaic acid on the apoptotic status of human HepaRG cells. Chem Biol Interact. 2020 Feb 1;317:108937.
38 Acrylamide exposure represses neuronal differentiation, induces cell apoptosis and promotes tau hyperphosphorylation in hESC-derived 3D cerebral organoids. Food Chem Toxicol. 2020 Oct;144:111643.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.